Profound Medical Corp.
TSX:PRN.TOMedical - Devices
+$0.11 today
- Market cap
- $360.04M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.00M
Average 0.01M
PRN.TO Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Profound Medical Corp.TSX: PRN.TO
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $5.25M rose 100.3% year over year, ahead of the +64.7% change in trailing-twelve-month revenue. Sequentially, it fell 13.5% from the prior quarter. Over 3 fiscal years it compounded at +34.8% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $25.71M (+57.0%) for the fiscal year ending Dec 2026, a step up from the +53.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.25M-13.5% QoQ
- Last fiscal yearDec 2025
- $16.38M+53.4% YoY
- LTMMar 2026
- $18.76M+64.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +100.3% | +114.7% | +14.5 pp |
| 1 year | +53.4% | +57.0% | +3.6 pp |
| 3-year CAGR | +34.8% | +56.9% | +22.0 pp |
| 5-year CAGR | +53.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 16.38M USD
- Year-over-year change
- +53.4%
- 4-year CAGR
- +24.2%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.38M | +53.4% |
| FY2024 | 2024-12-31 | 10.68M | +48.4% |
| FY2023 | 2023-12-31 | 7.2M | +7.8% |
| FY2022 | 2022-12-31 | 6.68M | -2.8% |
| FY2021 | 2021-12-31 | 6.87M | — |
Revenue vs competitors
How PRN.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +64.7% is the highest of 5, against a peer median of +1.2%.
- Over three fiscal years its annual growth of +34.8% compares with a peer median of -1.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | CA$374.61M CAD | +2.2% | -1.0% | |
| LTM Mar 2026 | $305.39M USD | +0.1% | -15.2% | |
| LTM Mar 2026 | CA$158.57M CAD | +22.2% | +17.0% | |
| LTM Mar 2026 | $55.76M USD | -1.8% | -2.8% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $18.76M USD | +64.7% | +34.8% |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding PRN.TO) | — | +1.2% | -1.9% | |
Competitors are the stored peer set for PRN.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.87M | 6.68M | 7.2M | 10.68M | 16.38M |
| Cost of Revenue | 3.92M | 3.66M | 2.82M | 3.64M | 4.79M |
| Gross Profit | 2.95M | 3.02M | 4.38M | 7.04M | 11.59M |
| Gross Margin | 43.0% | 45.2% | 60.9% | 65.9% | 70.8% |
| Research & Development | 15.28M | 14.69M | 14.38M | 16.97M | 20.96M |
| Selling, General & Admin | 17.97M | 17.93M | 18.62M | 23.13M | 32.61M |
| Operating Expenses | 33.24M | 32.62M | 33M | 40.1M | 53.57M |
| Depreciation & Amortization | 1.88M | 1.6M | 929K | 936K | 569.8K |
| EBITDA | (28.65M) | (26.6M) | (27M) | (32.13M) | (41.41M) |
| EBITDA Margin | -416.8% | -398.2% | -375.0% | -300.8% | -252.8% |
| Operating Income | (30.29M) | (29.6M) | (28.62M) | (33.06M) | (41.98M) |
| Operating Margin | -440.7% | -443.1% | -397.5% | -309.6% | -256.3% |
| Interest Income | 205K | 1.06M | 1.64M | 1.44M | 1.09M |
| Interest Expense | 67K | 168.82K | 770K | 0 | 0 |
| Other Income / Expenses | (303K) | 1.22M | 200K | 5.24M | (1.08M) |
| Income Before Tax | (30.59M) | (28.38M) | (28.7M) | (27.82M) | (43.06M) |
| Pre-Tax Margin | -445.1% | -424.8% | -398.6% | -260.5% | -262.9% |
| Income Tax Expense | 105K | 287K | (128K) | (2K) | 256.41K |
| Net Income | (30.7M) | (28.67M) | (28.57M) | (27.82M) | (43.32M) |
| Net Margin | -446.7% | -429.1% | -396.8% | -260.4% | -264.4% |
| EPS (Basic) | (1.50) | (1.38) | (1.35) | (1.12) | (1.43) |
| EPS (Diluted) | (1.50) | (1.38) | (1.35) | (1.12) | (1.43) |
| Weighted Avg Shares | 20.46M | 20.77M | 21.18M | 24.77M | 30.23M |
| Weighted Avg Shares (Diluted) | 20.47M | 20.77M | 21.18M | 24.77M | 30.23M |
Profound Medical Corp.
TSX:PRN.TO
Intrinsic Alpha fair value
Locked
Current Price
$9.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.